Deep Longevity, a San Diego, CA-based biotechnology company focused on improving longevity R&D through AI-discovered biomarkers of aging, raised a seed funding round of undisclosed amount.
The company has just come out of stealth from Insilico Medicine, the AI for drug discovery company recognized for its breakthroughs in generative chemistry, and generative biology.
The round was led by ETP Ventures and Human Longevity and Performance Impact Venture Fund, with participation from Bold Capital Partners, Longevity Vision Fund, Oculus co-founder and former chief software architect Michael Antonov through Formic Ventures, and LongeVC, as well as undisclosed investors including celebrity investors in artificial intelligence and some of the most prominent U.S. biotechnology investors.
Led by Alex Zhavoronkov, PhD, founder and CEO, Deep Longevity specializes in deep learning for aging research specializing in the development of deep biomarkers of aging using clinical blood tests, transcriptomic, proteomic, epigenetic, microbiome, behavioral, wearable, imaging, and multiple other data types. The company holds exclusive licenses to a comprehensive IP portfolio including both granted and pending patents. In the first partnership, the company will deploy its technology in a collaboration with Human Longevity, a genomics-based, health intelligence leader with a large database of sequenced genomes and phenotypic information.